Measuring revenue streams and profitability for HIV drugs

For-profit corporations invest considerable money in global health R&D in support of vaccine and drug development. According to a 2017 analysis, pharmaceutical firms devote nearly $157 billion annually on global health R&D. However, only $5.6 billion is focused on the developing world and $471 million emphasizes neglected tropical diseases. That money is far below what … Continue reading Measuring revenue streams and profitability for HIV drugs